Results 261 to 270 of about 47,423 (289)
Some of the next articles are maybe not open access.
Reno-protective effects of Phosphodiesterase 5 inhibitors
Clinical and Experimental Nephrology, 2021The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation, and red blood cell genesis. Kidney disease can be caused by various factors, including diabetes, ischemia/reperfusion injury, and nephrotoxic agents.
Enis Rauf Coskuner, Burak Ozkan
openaire +2 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources
ADMET considerations for phosphodiesterase-5 inhibitors
Expert Opinion on Drug Metabolism & Toxicology, 2012ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling is an important aspect of all drug developments. The pharmaceutical industry must always consider ADMET properties in order to optimize drug candidates and to introduce new formulations against existing marketed drugs.
Mohammad Amin, Rezvanfar +2 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, 2009Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire +2 more sources
Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design, 2006Phosphodiesterase 5 inhibitors, such as sildenafil, vardenafil and tadalafil, are now approved for the treatment of erectile dysfunction. They inhibit the cGMP-specific isoform 5 of phosphodiesterase, resulting in cGMP accumulation, which, for example in smooth muscle cells, reduces muscular tone.
Thorsten, Reffelmann, Robert A, Kloner
openaire +2 more sources
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Annals of Pharmacotherapy, 2005OBJECTIVETo review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED).DATA SOURCESPrimary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts ...
Stephen M, Setter +4 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: The Day After
European Urology, 2007Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis +1 more
openaire +2 more sources
Effect of phosphodiesterase-5 inhibitor on hearing
The Journal of Laryngology & Otology, 2009AbstractObjective:Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction.Methods:Eighteen patients ...
S, Okuyucu +4 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors for erectile dysfunction
BJU International, 2005This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire +2 more sources
Key Features for Designing Phosphodiesterase-5 Inhibitors
Journal of Biomolecular Structure and Dynamics, 2010Phosphodiesterase superfamily is the key regulator of 3',5'-cyclic guanosine monophosphate (cGMP) decomposition in human body. Phosphodiesterase-5 (PDE-5) inhibitors, sildenafil, vardenafil and tadalafil, are well known oral treatment for males with erectile dysfunction.
Tung-Ti, Chang +7 more
openaire +2 more sources